RF Acquisition Corp II(RFAI) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
September 11 at 7:30 PM ET (Korea 9/12 08:30)
Full metrics table
| Index | - | P/E | 322.96 | EPS (ttm) | 0.09 | Insider Own | 36.85% | Shs Outstand | 8.3M | Perf Week | -28.4% |
| Market Cap | 0.25B | Forward P/E | - | EPS next Y | - | Insider Trans | - | Shs Float | 5.3M | Perf Month | 171.91% |
| Enterprise Value | 0.25B | PEG | - | EPS next Q | - | Inst Own | 44.93% | Short Float | 0.34% | Perf Quarter | 173.89% |
| Income | 0.00B | P/S | - | EPS this Y | - | Inst Trans | - | Short Ratio | 0.17 | Perf Half Y | 175.89% |
| Sales | 0.00B | P/B | 6.74 | EPS next 5Y | - | ROA | 1.66% | Short Interest | 0.02M | Perf YTD | 180% |
| Book/sh | 4.47 | P/C | 25114.37 | EPS past 3/5Y | - | ROE | 1.76% | 52W High | -58.77% ($73.00) | Perf Year | 183.43% |
| Cash/sh | 0 | P/FCF | - | Sales past 3/5Y | - | ROIC | 3.07% | 52W Low | 236.69% ($8.94) | Perf 3Y | - |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -61.12% | Gross Margin | - | Volatility(W/M) | 12.37% 23.35% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 7.14 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 0.06 | EPS Q/Q | -82.21% | Profit Margin | - | RSI (14) | 48.11 | Recom | - |
| Dividend Gr. 3/5Y | - | Current Ratio | 0.06 | Sales Q/Q | - | SMA20 | -15.7% ($35.71) | Beta | 1.44 | Target Price | - |
| Payout | - | Debt/Eq | 0 | Earnings | - | SMA50 | 43.9% ($20.92) | Rel Volume | 0.07 | Prev Close | $32.01 |
| Employees | 2 | LT Debt/Eq | 0 | EPS/Sales Surpr. | - | SMA200 | 126.97% ($13.26) | Avg Volume(3M) | 0.11M | Price | $30.1 |
| IPO | 2024/7/5 | Option/Short | No/No | Trades | 436 | Volume | 7,729 | Change | -5.97% |
Company
RFAI is a Financial sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
🧬 This is a special purpose acquisition company (SPAC) pursuing a merger with Nanyang Biologics, a Singapore-based innovative AI-driven drug discovery company. The goal is to bring its unique platform technology—which leverages artificial intelligence to identify therapeutic compounds from natural products—to the public markets, driving innovation in the biotech industry.
Over the past 1 year, roughly in the middle
59% below its 1-year high.
RFAI has weak earning power
Tap to view numbers
The price looks about right
Trading at 323.0 times earnings.
Tap to view numbers
Holding long would have paid off
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership looks stable
Institutions hold 44.9%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
SPCZ 0.00%
RNMN 0.00%It ranks #4 in the industry
Based on market cap of $251M.
RFAI $251M PER 323.0
LION $3B PER -
BBCQ $2B PER -
CCXI $686M PER -
FAQ
What kind of company is RFAI?
RFAI belongs to the Financial sector and operates in the Shell Companies industry.
What is the market cap of RFAI?
The market cap of RFAI is approximately $251M, ranking 3,918 within its sector.
What is the P/E ratio of RFAI?
RFAI has a P/E ratio of approximately 323.0x, which can be used to assess its valuation relative to the Financial sector average.
What is the 52-week high and low for RFAI?
RFAI has recorded a 52-week high of $73.00 and a low of $8.94.
